Covid-19: SEC approves Corbevax for use in kids aged 5-12 years

Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) on Thursday recommended the use of Biological E's Corbevax in children between 5-12 years, amid an uptick in the number of cases among school going children. The recommendation has now been sent to the DCGI, who will give his final nod.

Corbevax is currently being administered to children in the age group 12-14 years. Hyderabad based Biological E had approached the drug regulator earlier this week for granting Emergency Use Authorisation (EUA). However, the SEC sought more data.

In a meeting held on April 11, the SEC reviewed Biological E's application and asked for updated safety data which should be 2-3 months post second dose, immunogenicity data and virus neutralising antibody data against a variant of concern.


The SEC has also sought additional data from Bharat Biotech for using Covaxin in kids between 5-12 age group.